Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: hatanaka t. Aliment Pharmacol Ther. 2024 Jul;60(2):233-245. doi: 10.1111/apt.18037. Epub 2024 May 8. Aliment Pharmacol Ther. 2024. PMID: 38716823 Clinical Trial.
Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015.
Yamazaki Y, Naganuma A, Arai Y, Takeuchi S, Kobayashi T, Takakusagi S, Hatanaka T, Hoshino T, Namikawa M, Hashizume H, Takizawa D, Ohyama T, Suzuki H, Horiguchi N, Takagi H, Sato K, Kakizaki S, Kusano M, Nagashima S, Takahashi M, Okamoto H, Yamada M. Yamazaki Y, et al. Among authors: hatanaka t. Hepatol Res. 2017 Apr;47(5):435-445. doi: 10.1111/hepr.12765. Epub 2016 Jul 27. Hepatol Res. 2017. PMID: 27322051
Early Decreases in α-Fetoprotein and Des-γ-carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma.
Hatanaka T, Kakizaki S, Shimada Y, Takizawa D, Katakai K, Yamazaki Y, Sato K, Kusano M, Yamada M. Hatanaka T, et al. Intern Med. 2016;55(16):2163-71. doi: 10.2169/internalmedicine.55.6688. Epub 2016 Aug 15. Intern Med. 2016. PMID: 27522991 Free article.
Isolated Gastric Varices Refractory to Balloon-occluded Retrograde Transvenous Obliteration (BRTO) Successfully Treated by Shunt-occluded Endoscopic Injection Sclerotherapy (SO-EIS): A Case Report and Review of the Literature.
Hatanaka T, Kakizaki S, Suzuki Y, Ueno T, Shimada Y, Takizawa D, Katakai K, Sato K, Kusano M, Yamada M. Hatanaka T, et al. Intern Med. 2017;56(9):1041-1048. doi: 10.2169/internalmedicine.56.7761. Epub 2017 May 1. Intern Med. 2017. PMID: 28458309 Free PMC article. Review.
Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin.
Sato K, Naganuma A, Nagashima T, Hoshino T, Uehara D, Arai Y, Horiuchi K, Yuasa K, Takayama H, Arai H, Hatanaka T, Ohyama T, Tahara H, Sohara N, Kobayashi T, Horiguchi N, Yamazaki Y, Kakizaki S, Kusano M, Yamada M, Murase T, Nakamura T. Sato K, et al. Among authors: hatanaka t. Hepatol Res. 2018 Feb;48(3):E347-E353. doi: 10.1111/hepr.12971. Epub 2017 Sep 25. Hepatol Res. 2018. PMID: 28834004
541 results